NCT03579121

Genomic Opioid Optimization of Dosing and Selections (GOODS) Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The researchers are conducting this study to see if pharmacogenomic testing before surgery helps the doctor to choose which medications will work best for the patient.

Detailed description

Participants, undergoing total knee replacements, will be randomized into two groups. Both groups will receive pharmacogenomics (PGx) testing preoperatively. The PGx guided group will have their results reviewed by the clinicians during their treatment and the results may guide clinical decisions. The control group results will be sealed until completion of treatment and clinicians will not have access to this information. These participants will undergo standard treatment dosing and medication selection.

Conditions

• Perioperative/Postoperative Complications

Interventions

Type	Name	Description
OTHER	Pharmacogenomic (PGx)	Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
OTHER	Review results	Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.

Timeline

• Start date: 2018-10-12
• Primary completion: 2022-03-01
• Completion: 2022-04-01
• First posted: 2018-07-06
• Last updated: 2022-06-15

Locations

1 site across 1 country: United States